SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1132)12/31/1998 3:42:00 PM
From: Ibexx  Respond to of 1580
 
Henry,

The inserts will tell the story. Don't worry.

Ibexx



To: Henry Niman who wrote (1132)1/4/1999 11:20:00 PM
From: Brian Malloy  Read Replies (2) | Respond to of 1580
 
FDA Approves New Painkiller But Says No Proof It's Easier on Patients' Stomachs
abcnews.go.com

Let's see how things end up for MRK and Vioxx. Vioxx has gone through much more testing than Celebra to include giving people 10X the normal dose without GI side effects if I remember correctly. Once a day dosing, and wider FDA approved use to boot as well.

If MRK is able to say reduced chance of Ulcers then MRK is off to the races this spring.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News